The U.S. House passed the Full-Year Continuing Appropriations and Extensions Act – ACS CAN
American Cancer Society Cancer Action Network (ACS CAN) posted on LinkedIn:
“Breaking: Today, the U.S. House passed the Full-Year Continuing Appropriations and Extensions Act. It contains no increases for federal Cancer Research or prevention funding and significant cuts to Congressionally Directed Medical Research Programs (CDMRP), in which cancer is the largest recipient of funds.
‘A 57% reduction in CDMRP appropriation will most certainly risk vital advances in cancer research, halting much needed innovation,’ says Lisa A. Lacasse, president of ACS CAN. ‘CDMRP is responsible for several clinical cancer advancements, especially for prostate cancer, the most diagnosed cancer and the second most common cause of cancer-related death for men in the United States.
Cancer patients and their families rely on Congress to maintain the critical role of government in the cancer fight, because robust funding is not just an investment in science but a commitment to patient’s lives.
ACS CAN calls on Congress to reinvest in the fight against cancer by prioritizing investments in research and prevention that will end cancer as we know it, for everyone.’
Lisa A. Lacasse, President of the American Cancer Society Cancer Action Network, shared this post on LinkedIn, adding:
“With advancements in cancer treatment and early detection largely reliant on sustained research and prevention efforts, any reduction in federal support could significantly impede progress and jeopardize the lives of millions facing this devastating disease.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023